Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Reports Next Week: Wall Street Expects Earnings Growth

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the third quarter of fiscal year 2022 ended March 31, 2022, before the market open on Tuesday, May 3, 2022. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET o

Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast

Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.

Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Catalent (CTLT) is a Strong Momentum Stock

Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.

Catalent's (CTLT) New Project Completion Expands Global Footprint

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will virtually present at the KeyBanc Life Sciences & MedTech Investor Forum at 10:30 a.m. ET on March 23, 2022. A live webcast of the presentation will be accessible at http://investor.catalent.com and will

Catalent, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum

We believe that Catalent stock, a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, currently is an attractive pick over West Pharmaceutical Services, best known for injectable pharmaceutical packaging and delivery systems, given its comparatively.

Is There A Better Pick Over West Pharmaceutical Services Stock?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today published its Corporate Responsibility (CR) Report for its most recent fiscal year, which ended June 30, 2021. The report is the third since Catalent launched its CR strategy to address a wide range of environmental, social, and governance (ESG) to

Catalent Publishes Third Annual Corporate Responsibility Report

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

Catalent's (CTLT) New Tie-Up to Provide Better Patient Access

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent (CTLT) Down 3.4% Since Last Earnings Report: Can It Rebound?

PARSIPPANY, N.J.--(BUSINESS WIRE)--Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that DARTISLA ODT (glycopyrrolate) is now available by prescription in the United States through Phil, the commercialization partner and eHub for DARTISLA ODT, as well as in retail pharmacies throughout the country. To ensure access to patients in need, Edenbridge is sponsoring the DARTISLA ODT Copay Program, which allows eligible patients to obtain the product for as little as $0 when filled throu

Edenbridge Pharmaceuticals Announces the Launch of DARTISLA ODT

Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2022 Results - Earnings Call Transcript

Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.

Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up

Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates

Catalent Inc CTLT has reported Q2 FY22 sales of $1.22 billion, +34% Y/Y as reported, or 35% in constant currency, edging out analysts' average expectation of $1.15 billion. [LIVE NOW ON YOUTUBE] Click Here to Watch a FREE MASTERCLASS on the Ultimate Bear Market Survival Guide with Matt Maley!

Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2022, which ended December 31, 2021. “Our second quarter results demonstrated steady momentum across our businesses, and we expect favorable market dynamics will continue to fuel long-term grow

Catalent, Inc. Reports Second Quarter Fiscal 2022 Results

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Earnings Expected to Grow: Should You Buy?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2022 ended December 31, 2021, before the market open on Tuesday, February 1, 2022. The Company's management will host a webcast to discuss the results at 8:15

Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.

Catalent (CTLT) to Advance Oral Drug Development With New Launch

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company's next President and Chief Executive Officer, effective July 1, 2022. Maselli will also join the company's Boa

Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that members of its executive leadership team will virtually present at the 40th Annual J.P. Morgan Healthcare Conference at 7:30 a.m. ET on January 10, 2022. A live webcast of the presentation will be accessible at http://investor.cata

Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that it has received approval from the U.S. Food and Drug Administration on its 505(b)(2) New Drug Application (NDA) for DARTISLA ODT (glycopyrrolate) orally disintegrating tablets. DARTISLA ODT is available in a 1.7 mg orally disintegrating tablet and is indicated for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. Edenbridge will launch this product to the

News for Catalent Stock (CTLT)